CD274 and neoplasm: Overall, the different clinical trials that targeted the PD-L1/PD-1 axis demonstrated a relatively low-to-moderate improvement in objective response rates in TNBC patients; in most cases, effectiveness was increased by chemotherapies, possibly due to the exposure of neo-antigens, leading to increased activation of anti-tumor immune responses [11,14,15,16,17,18,19,20,21,22,23].